APA (7th ed.) Citation

Fossa, A., Molin, D., Broeckelmann, P. J., Schneider, G., Schnetzke, U., Linderoth, J., . . . Böll, B. (2025). Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy. HemaSphere, 9(3), . https://doi.org/10.1002/hem3.70099

Chicago Style (17th ed.) Citation

Fossa, Alexander, et al. "Brentuximab Vedotin Monotherapy Is a Feasible and Effective Treatment for Older Patients with Classical Hodgkin Lymphoma Unsuitable for Curative Chemotherapy." HemaSphere 9, no. 3 (2025). https://doi.org/10.1002/hem3.70099.

MLA (9th ed.) Citation

Fossa, Alexander, et al. "Brentuximab Vedotin Monotherapy Is a Feasible and Effective Treatment for Older Patients with Classical Hodgkin Lymphoma Unsuitable for Curative Chemotherapy." HemaSphere, vol. 9, no. 3, 2025, https://doi.org/10.1002/hem3.70099.